שווי כולל של החברה: DBV Technologies (DBVT)

The competitive advantage of DBV Technologies S.A. (DBVT) is based on unique patents for epicutaneous allergy therapy, which create a significant technological barrier. Business success depends on FDA approval of Viaskin patches, their safety for children, and established distribution channels. This price chart reflects an Enterprise Value of 473.34, while global conflicts and sanctions complicate biomaterial logistics and the conduct of international studies.

An analysis of historical EV levels demonstrates the market value of DBV Technologies S.A. (DBVT) as a biotech issuer with a critical dependence on a single product. This metric aggregates market capitalization and net debt to determine the actual cost of acquiring the business, which, given the single-product imbalance, makes the valuation extremely sensitive to regulatory verdicts on platform approval and the risk of capital freezes.